Posts tagged “GSK”

Updated January 19

Premium Lock GSK pharma chief to quit after losing out on CEO job

GSK's HQ in London               GlaxoSmithKline's head of pharmaceuticals is leaving the drug giant after losing out in the race to replace retiring CEO Andrew Witty. GSK is hiring an AstraZeneca exec to replace him.

December 20, 2016

Premium Lock GSK launches trial for long-acting injection to prevent HIV

HIV AIDS research   GlaxoSmithKline's ViiV Healthcare is launching a phase 3 clinical trial of a long-lasting injection that could prevent the HIV virus.

December 5, 2016

Premium Lock GSK names new leader for ViiV Healthcare

ViiV Healthcare Dr. Dominique Limet is leaving after seven years as the CEO of GSK-owned ViiV Healthcare, which focuses on treatments for HIV. He will be replaced by GSK executive Deborah Waterhouse.

November 18, 2016

Premium Lock GSK awards $400,000 to Triangle nonprofits

GSK in Zebulon   GlaxoSmithKline hands out $400,000 in grants to 10 Triangle area nonprofits as part of its GSK Impact Awards.

Tags: GSK
October 24, 2016

Premium Lock Got a cough? GSK adding IBM's Watson to help you find answers

IBM Watson avatar     As WRAL TechWire has reported extensively over the past few months, IBM keeps adding to the capabilities of its Watson supercomputer services. Now, drug giant GSK is incorporating Watson interactive artificial intelligence into an advertising campaign for its cough and cold advertising.

October 24, 2016

Premium Lock GSK seeks US approval for blockbuster shingles vaccine

GSK's HQ in London               GlaxoSmithKline is seeking FDA approval for its new shingles vaccine, a drug that analysts say could be a $1 billion-a-year blockbuster.

Updated October 3, 2016

Premium Lock GSK to pay $20M to resolve SEC charges in China bribery case+ SEC case summary

GSK in Zebulon   GlaxoSmithKline has agreed to pay $20 million to resolve U.S. regulators' allegations that the pharmaceutical giant's China operations bribed officials to boost drug sales. Plus: Read the SEC summary of the case.

Updated September 20, 2016

Premium Lock GSK names Emma Walmsley to replace Andrew Witty as CEO

GlaxoSmithKline picks Emma Walmsley, a female executive of its management team, to replace CEO Andrew Witty when he retires early next year. Plus: Read her bio, watch video about the news.

September 12, 2016

Premium Lock GSK sells anesthetic meds to Aspen in $372M deal

GSK's HQ in London               GlaxoSmithKline is selling its anesthetic medicine portfolio to Aspen Pharmacare in a deal worth as much as $372 million. GSK had already sold the drugs involved in U.S. and Canadian markets.

Updated August 19, 2016

Premium Lock GSK is No. 1 on Fortune 'Change the World' list; Novozymes 9th, IBM 47th

Fortune GlaxoSmithKline takes home the honor as the top business on Fortune's annual "Change the World" list. Two other tech/biotech companies with a big North Carolina presence also are recognized: Novozymes and IBM.

August 19, 2016

Premium Lock Mayne Pharma's $50M GSK deal; UNC-CH opioid drug project; SAS targets heat, disease; RTI's $2M biofuels deal

Triangle headlines In today's wrapup of tech and life science headlines from around the Triangle region: Mayne Pharma spends $50 million to acquire some GSK dermatology assets; UNC-CH researchers help develop an opioid drug candidate from scratch; SAS works with an Arizona county to fight heat and disease; and RTI International lands a $2M-plus biofuels contract.

Updated August 2, 2016

Premium Lock GSK, Google subsidiary form $714M bioelectronics venture (+ video)

‚ÄčOne of Google's sister companies will team up with pharmaceuticals firm GlaxoSmithKline to form a joint venture that aims to develop tiny implants that can tap nerves and change their electronic signals as a way of treating chronic illnesses.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith